Goldman Sachs Maintains Neutral on Calumet, Raises Price Target to $45
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $40 to $45.
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $40 to $45.